Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder
Portfolio Pulse from Vandana Singh
Addex Therapeutics and Indivior have selected a compound for substance use disorder treatment, with Addex eligible for up to $330 million in milestone payments. Addex will also advance its own compound for chronic cough. Previously, Janssen Pharmaceuticals, a Johnson & Johnson unit, discontinued a compound for epilepsy.
August 27, 2024 | 12:48 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Johnson & Johnson's unit, Janssen Pharmaceuticals, discontinued the development of an epilepsy compound after it failed to meet primary endpoints in a Phase 2 trial.
The discontinuation of the epilepsy compound by Janssen is a setback, potentially impacting J&J's R&D efforts negatively.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Addex Therapeutics' stock surged due to the selection of a compound for substance use disorder, potentially earning up to $330 million in milestone payments. The company is also advancing a compound for chronic cough.
The selection of a compound for substance use disorder and potential milestone payments are significant positive developments for Addex, driving the stock price higher.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Indivior has selected a compound for substance use disorder from its collaboration with Addex, taking over future development. This could enhance Indivior's pipeline and market position.
Indivior's selection of a compound for substance use disorder strengthens its development pipeline, which is a positive indicator for future growth.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 70